DE68905438D1 - Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose. - Google Patents

Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.

Info

Publication number
DE68905438D1
DE68905438D1 DE8989850317T DE68905438T DE68905438D1 DE 68905438 D1 DE68905438 D1 DE 68905438D1 DE 8989850317 T DE8989850317 T DE 8989850317T DE 68905438 T DE68905438 T DE 68905438T DE 68905438 D1 DE68905438 D1 DE 68905438D1
Authority
DE
Germany
Prior art keywords
pharmaceutical preparations
interferon gamma
vascular stenosis
treatment
treating vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8989850317T
Other languages
English (en)
Other versions
DE68905438T2 (de
Inventor
Goeran Hansson
Jan Holm
Lena Jonasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE68905438D1 publication Critical patent/DE68905438D1/de
Application granted granted Critical
Publication of DE68905438T2 publication Critical patent/DE68905438T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE89850317T 1988-09-30 1989-09-27 Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose. Expired - Lifetime DE68905438T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos

Publications (2)

Publication Number Publication Date
DE68905438D1 true DE68905438D1 (de) 1993-04-22
DE68905438T2 DE68905438T2 (de) 1993-09-30

Family

ID=20373494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89850317T Expired - Lifetime DE68905438T2 (de) 1988-09-30 1989-09-27 Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose.

Country Status (18)

Country Link
US (1) US5208019A (de)
EP (1) EP0367735B1 (de)
JP (1) JP2895896B2 (de)
KR (1) KR0137017B1 (de)
AT (1) ATE86869T1 (de)
AU (1) AU623181B2 (de)
CA (1) CA1338722C (de)
DD (1) DD288094A5 (de)
DE (1) DE68905438T2 (de)
DK (1) DK174523B1 (de)
HU (1) HU206988B (de)
IE (1) IE63874B1 (de)
IL (1) IL91796A (de)
NZ (1) NZ230816A (de)
PH (1) PH26293A (de)
PT (1) PT91863B (de)
SE (1) SE462364B (de)
WO (1) WO1990003189A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2131550A1 (en) * 1992-02-05 1993-08-19 Andrew Zalewski Interferon gene therapy for the treatment of vascular disorders
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
JPH08505397A (ja) * 1993-01-07 1996-06-11 トーマス ジェファーソン ユニバーシティ 平滑筋細胞の増殖を調節するためのｃ‐ｍｙｃのアンチセンス阻害
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
EP0797998A4 (de) * 1995-11-17 2003-01-15 Toray Industries Schutz für endothelzellen
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
DE69932235T2 (de) 1998-04-02 2007-06-14 Genentech, Inc., South San Francisco Behandlung von herzhypertrophie
US7524826B2 (en) * 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3261761D1 (en) * 1981-07-14 1985-02-14 Efamol Ltd Pharmaceutical and dietary composition when used for enhancement of 1-series pg production
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4454115A (en) * 1981-10-23 1984-06-12 Wisconsin Alumni Research Foundation Method of reducing the level of low density lipoproteins in the serum of a patient
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
NZ230816A (en) 1997-06-24
IE893123L (en) 1990-03-30
US5208019A (en) 1993-05-04
DK56291D0 (da) 1991-03-27
JP2895896B2 (ja) 1999-05-24
AU4305189A (en) 1990-04-18
JPH04500966A (ja) 1992-02-20
PT91863B (pt) 1995-05-31
DK174523B1 (da) 2003-05-12
PT91863A (pt) 1990-03-30
KR0137017B1 (ko) 1998-04-25
AU623181B2 (en) 1992-05-07
CA1338722C (en) 1996-11-19
HUT57063A (en) 1991-11-28
DE68905438T2 (de) 1993-09-30
DK56291A (da) 1991-05-24
IE63874B1 (en) 1995-06-14
ATE86869T1 (de) 1993-04-15
SE8803472D0 (sv) 1988-09-30
IL91796A (en) 1994-10-07
IL91796A0 (en) 1990-06-10
PH26293A (en) 1992-04-10
HU895542D0 (en) 1991-10-28
DD288094A5 (de) 1991-03-21
SE462364B (sv) 1990-06-18
EP0367735B1 (de) 1993-03-17
EP0367735A1 (de) 1990-05-09
KR900701308A (ko) 1990-12-01
WO1990003189A1 (en) 1990-04-05
HU206988B (en) 1993-03-01

Similar Documents

Publication Publication Date Title
DE68905438D1 (de) Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.
ATE302599T1 (de) Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
DE69121704D1 (de) Kombinationskatheter zur beobachtung und zur dilatation von blutgefässen
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DK399288D0 (da) Dobbeltstrenget rna-korrektion af abnormiteter i cirkulerende immunkomplekser og monocytfunktion
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
BR9007115A (pt) Novo trombolitico
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
DK0821969T3 (da) Medicinsk sammensætning omfattende TCF-II
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
ATE171071T1 (de) Verfahren und zusammensetzungen zur verminderung von blutverlust
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
ATE193450T1 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenbrüchen
ATE66147T1 (de) Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
DE69635131D1 (de) Verwendung von beta-interferon zur behandlung der restenose
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69231465T2 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ATE476182T1 (de) Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs
DE68912432D1 (de) Pharmazeutische Zusammensetzung, verwendbar bei der Behandlung von Herzgefässerkrankungen.
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GENENTECH, INC. (N.D.GES.D.STAATES DELAWARE), SOUT

8381 Inventor (new situation)

Free format text: HANSSON, GOERAN, GOETEBORG, SE HOLM, JAN, GOETEBORG, SE JONASSON, LENA, EKSJOE, SE